Published in
Society of Nuclear Medicine, Journal of Nuclear Medicine, 1(53), p. 29-36, 2011
DOI: 10.2967/jnumed.111.092387
Links
- ORCID
- Society of Nuclear Medicine
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
3′-Deoxy-3′-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab
Journal article published in 2011 by
Johannes Schwarzenberg,
Johannes Czernin,
Timothy F. Cloughesy,
Benjamin M. Ellingson,
Whitney B. Pope 
,
Cheri Geist,
Magnus Dahlbom,
Daniel H. S. Silverman,
Nagichettiar Satyamurthy,
Michael E. Phelps,
Wei Chen
,
Cheri Geist,
Magnus Dahlbom,
Daniel H. S. Silverman,
Nagichettiar Satyamurthy,
Michael E. Phelps,
Wei Chen
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
With the dismal prognosis for malignant glioma patients, survival predictions become key elements in patient management. This study compares the value of 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) PET and MRI for early outcome predictions in patients with recurrent malignant glioma on bevacizumab therapy.